

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 22083-008US1	Application No. 10/553,152
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Burnie <i>et al.</i>	
		Filing Date August 4, 2006	Group Art Unit 1645
(37 CFR §1.98(b))			

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A1	6,291,158	09/18/2001	Winter <i>et al.</i>			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	B1	EP 0 368 684	05/16/1990	EPO				
	B2	EP 0 376 851	07/04/1990	EPO				
	B3	WO 91/09967	07/11/1991	WIPO				
	B4	WO 01/27279	04/19/2001	WIPO				
	B5	WO 01/44300	06/21/2001	WIPO				
	B6	WO 01/96599	12/20/2001	WIPO				
	B7	WO 02/055559	07/18/2002	WIPO				
	B8	WO 02/062379	08/15/2002	WIPO				
	B9	WO 03/048321	06/12/2003	WIPO				
	B10	WO 04/094474	11/04/2004	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	C1	Burgess <i>et al.</i> , "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue" <i>J. Cell Biology</i> 111:2129-2138 (1990)
	C2	Burgoon <i>et al.</i> , "Cloning the Antibody Response in Humans with Inflammatory Central Nervous System Disease: Analysis of the Expressed IgG Repertoire in Subacute Sclerosing Panencephalitis Brain Reveals Disease-Relevant Antibodies That Recognize Specific Measles Virus Antigens" <i>J. Immunol.</i> 163(6):3496-3502 (1999)
	C3	Casset <i>et al.</i> , "A peptide Mimetic of an anti-CD4 monoclonal antibody by rational design" <i>BBRC</i> 307:198-205 (2003)
	C4	Chen <i>et al.</i> , "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen" <i>J. Mol. Biol.</i> 293:865-881 (1999)
	C5	Colman "Effects of amino acid sequence changes on antibody-antigen interactions" <i>Res. in Immunol.</i> 145:33-36 (1994)
	C6	Currier <i>et al.</i> , "Mitogens, Superantigens, and Nominal Antigens Elicit Distinctive Patterns of TCRB CDR3 Diversity" <i>Human Immunol.</i> 48:39-51 (1996)
	C7	Desiderio <i>et al.</i> , "A Semi-synthetic Repertoire of Intrinsically Stable Antibody Fragments Derived from a Single-framework Scaffold" <i>J. Mol. Biol.</i> 310:603-615 (2001)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 22083-008US1	Application No. 10/553,152
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Burnie <i>et al.</i>	
		Filing Date August 4, 2006	Group Art Unit 1645

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	C8	Holm <i>et al.</i> , "Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1" <i>Mol. Immunol.</i> 44:1075-1084 (2007)
	C9	Lazar <i>et al.</i> , "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities" <i>Mol. Cell. Biol.</i> 8(3):1247-1252 (1988)
	C10	Lewis <i>et al.</i> , "Use of a Novel Mutagenesis Strategy, Optimized Residue Substitution, to Decrease the Off-Rate of an Anti-gp120 Antibody" <i>Mol. Immunol.</i> 32(14/15):1065-1072 (1995)
	C11	Lin <i>et al.</i> , "Structure-Function Relationships in Glucagon: Properties of Highly Purified Dis-His ⁻ , Monoiodo-, and [Des-Asn ²⁸ , Thr ²⁹] (homoserine lactone ²⁷)-glucagon" <i>Biochem. USA</i> 14:1559-1563 (1975)
	C12	Panka <i>et al.</i> , "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies" <i>PNAS USA</i> 85(9):3080-3084 (1988)
	C13	Rinaldi <i>et al.</i> , "Antibodies Elicited by Naked DNA Vaccination Against the Complementary-determining Region 3 Hypervariable Region of Immunoglobulin Heavy Chain Idiotype Determinants of B-lymphoproliferative Disorders Specifically React with Patients' Tumor Cells" <i>Cancer Res.</i> 61:1555-1568 (2001)
	C14	Rinaldi <i>et al.</i> , "Strategies to Elicit Anti-Idiotype Immune Response in B-Lymphoma Patients" <i>Gene Therapy of Cancer</i> edited by Walden <i>et al.</i> Plenum Press, New York, 323-330 (1998)
	C15	Rudikoff <i>et al.</i> , "Single amino acid substitution altering antigen-binding specificity" <i>PNAS USA</i> , 79(6):1979-1983 (1982)
	C16	Schwartz <i>et al.</i> , "A superactive insulin: [B10-Aspartic acid]insulin(human)" <i>PNAS USA</i> 84:6408-6411 (1987)
	C17	Slivkowski <i>et al.</i> , "Incorporation and Distribution of Selenium Into Thiolase From Clostridium-Kluyveri", <i>J. Biol. Chem.</i> 260(5): 3140-3144 (1985)
	C18	Wen <i>et al.</i> , "In-vivo immune response to idiotype VH complementarity-determining region 3 peptide vaccination in B-cell non-Hodgkins lymphoma" <i>British J. Haematology</i> 103:663-668 (1998)
	C19	Winzer <i>et al.</i> , "Differential Regulation of Two Thiolase Genes from Clostridium acetobutylicum DSM 792" <i>J. Mol. Microbiology and Biotechnology</i> 2(4): 531-541 (2000)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	